Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma
PD-1 inhibitor monotherapy produces an impressive response. Eight gene mutations were significantly more frequent in non-responders. PD-L1 and TMB were inconclusive in predicting treatment response to anti-PD-L1.
Authors
- Cetin Urtis
- Lauren Schmalz
- Mark J. Chang
- Nathan L. Bowers
- Thomas Lycan (ORCID: https://orcid.org/0000-0001-9475-1558)
- Abdur Rahman Jabir (ORCID: https://orcid.org/0000-0003-2166-1513)
- Laura Doerfler
- J. Dale Browne
- Paul M. Bunch (ORCID: https://orcid.org/0000-0001-6129-7299)
- Hafiz S. Patwa
- Daniel B. Stamos (ORCID: https://orcid.org/0000-0002-9646-0831)
- Mercedes Porosnicu (ORCID: https://orcid.org/0000-0003-3651-8867)
- Logan Deyo
- Wei Zhang (ORCID: https://orcid.org/0000-0002-2235-1851)
- Christopher A. Sullivan
- Joshua D. Waltonen
- Martin F. Porebski
Institutions
- Atrium Health Wake Forest Baptist (US)
- Wake Forest Baptist Comprehensive Cancer Center
- Wake Forest University (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3390/cancers17071172
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Cancer Institute